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with glomerular filtration rate (GFR) and were 
an independent risk marker of progression to 
end ‑stage renal disease and mortality.5 In pa‑
tients on hemodialysis (HD), the plasma ADMA 
level is a strong and independent predictor of 
overall mortality and cardiovascular outcome.6 
ADMA is a natural inhibitor of nitric oxide (NO) 
INTRODUCTION Elevated plasma concentrations 
of asymmetric dimethylarginine (ADMA) are as‑
sociated not only with endothelial dysfunction 
and atherosclerosis but also predict mortality and 
cardiovascular complications.1-4 In patients with 
mild to advanced chronic kidney disease (CKD), 
plasma ADMA levels were inversely correlated 
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ABSTRACT
INTRODUCTION Medial arterial calcification is common in patients with chronic kidney disease (CKD) 
and is considered a risk factor for morbidity and mortality.
OBJECTIVES We aimed to evaluate the correlation between asymmetric dimethylarginine (ADMA) levels, 
radial artery calcification, and common carotid artery intima–media thickness (CCA ‑IMT).
PATIENTS AND METHODS The study included 51 patients with CKD, in whom an arteriovenous fistula for 
hemodialysis access was created to collect radial artery samples for a histological examination, and 
33 healthy volunteers, in whom the reference concentrations of ADMA were assessed. The concentra‑
tions of creatinine, albumin, calcium, phosphate, fibroblast growth factor 23, osteoprotegerin (OPG), 
osteopontin (OPN), osteocalcin, secreted protein acidic and rich in cysteine, interleukin 6, interleukin 18, 
pentraxin 3, stromal cell ‑derived factor 1α (SDF1α), thrombomodulin, soluble tumor necrosis factor recep‑
tor II (sTNFRII), and matrix metalloproteinase 2 (MMP ‑2) were determined. Radial artery fragments were 
stained for calcifications using alizarin red. The CCA ‑IMT was assessed by ultrasonography.
RESULTS Patients with CKD had higher ADMA levels than controls. Patients with ADMA levels above 
the median were older, had higher levels of phosphate, fibroblast growth factor 23, OPG, OPN, PTX3, 
sTNFRII, MMP ‑2, thrombomodulin, and they had more atherosclerotic plaques in the carotid artery. In 
multiple regression, log ‑transformed (log)sTNFRII, MMP ‑2, and SDF1α levels were independent predictors 
of log(ADMA). Patients with calcifications had higher ADMA levels. A similar correlation was observed 
between SDF1α and alizarin red staining grades 1 to 3. In logistic regression, ADMA levels positively 
predicted the presence of calcifications independently of age, hemodialysis status, Framingham risk 
score, and PTX3.
CONCLUSIONS Circulating ADMA levels indicate medial arterial calcification in patients with CKD.
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Harmonization/Good Clinical Practice regula‑
tions. The study was approved by the Bioethics 
Committee of the Jagiellonian University and all 
patients signed an informed consent for partici‑
pation in the study.
Histology Small fragments of the radial artery 
wall were collected during the first creation of 
an arteriovenous fistula for HD access. Briefly, 
tissue sections were stained with alizarin red to 
detect calcium (Ca) deposits and then subjected 
to microscopic assessment. The stained sections 
were examined using an Olympus BX ‑50 micro‑
scope (Olympus, Tokyo, Japan) in the bright‑
field mode, and the images were registered using 
Olympus DP ‑71 digital CCD camera controlled 
by Olympus AnalySIS FIVE software. An experi‑
enced histologist evaluated the sections in a blind‑
ed manner.
The advancement of vascular calcification was 
evaluated semiquantitatively, and the degree of 
mineralization was classified according to the fol‑
lowing scale: 0, no mineral content; 1, a few small 
dispersed concretions; 2, numerous small dis‑
persed concretions; 3, larger granular concre‑
tions; and 4, large areas occupied by fused min‑
eral deposits. The calcifications were found ex‑
clusively in the vascular media (FIGURE 1). The re‑
producibility of the morphological analysis was 
confirmed by the Bland–Altman method and by 
calculating an intraclass correlation coefficient, 
which was 0.88.
Laboratory tests The levels of the following bio‑
chemical parameters were measured in all pa‑
tients: creatinine, glucose, intact parathyroid hor‑
mone (iPTH), total Ca and phosphate (Pi), ADMA, 
stromal cell ‑derived factor 1α (SDF1α), MMP ‑2, 
interleukin 6 (IL ‑6), interleukin 18 (IL ‑18), pen‑
traxin 3 (PTX3), soluble tumor necrosis factor 
receptor II (sTNFRII), thrombomodulin (TM), 
osteoprotegerin (OPG), osteopontin (OPN), os‑
teocalcin (OC), secreted protein acidic and rich 
in cysteine (SPARC), and fibroblast growth fac‑
tor 23 (FGF ‑23). The estimated GFR was calculat‑
ed by the Modification of Diet in Renal Disease 
formula: estimated GFR = (186 × serum creatinine 
[μmol/l] × 0.0113)–1.154 × age –0.203 × 114 × (0.742 for 
women).
A sample of peripheral venous blood was col‑
lected at fasting into EDTA tubes in the morning 
prior to creation of the arteriovenous fistula, and 
plasma was kept frozen at −70°C for subsequent 
biochemical analyses. Routine biochemical tests 
were carried out using automatic biochemical an‑
alyzers: Hitachi 917 (Hitachi, Japan) and Modu‑
lar P (Roche Diagnostics, Mannheim, Germany).
ADMA levels in platelet ‑poor EDTA plas‑
ma were measured by a commercially available 
ADMA ELISA kit (DLD Diagnostika GmbH, Ham‑
burg, Germany). The detection limit for the as‑
say was 0.04 μmol/l. The intra‑assay and interas‑
say precision was 10.8% and 7.9%, respectively. 
The cross reactivity of L ‑arginine and symmetric 
synthase and serum ADMA levels are strongly 
correlated with impaired flow ‑mediated vasodi‑
latation and with the common carotid artery inti‑
ma–media thickness (CCA ‑IMT). NO plays a cru‑
cial role in vascular protection because it inhibits 
proliferation and migration of vascular smooth 
muscle cells, expression of adhesion molecules, 
and platelet aggregation.7 A 3‑ to 9 ‑fold increase 
of plasma ADMA levels was shown to inhibit NO 
production by 30% to 70%.6 Elevated ADMA lev‑
els lead to myocardial fibrosis and microvascu‑
lar dropout by directly influencing endothelial 
cells and fibroblasts and by indirectly stimulat‑
ing the production of additional potent angio‑
genesis inhibitors.8
The aim of the present study was to evaluate 
the correlation between circulating ADMA lev‑
els and radial artery calcification in patients with 
CKD. We also studied the associations between 
serum ADMA levels and selected markers of in‑
flammation, mineral and bone disorder, endothe‑
lial dysfunction, as well as matrix metalloprotein‑
ase 2 (MMP ‑2).
PATIENTS AND METHODS The study group in‑
cluded 51 patients with CKD (20 women, 31 men; 
21 predialysis patients, 30 HD patients) and 
33 healthy volunteers matched for age and sex 
who were recruited to assess the reference ADMA 
concentrations. The mean (SD) age of patients was 
62 (16) years. Patients had an arteriovenous fis‑
tula for HD access created for the first time, al‑
lowing a collection of radial artery samples for 
a histological examination. The autologous ar‑
teriovenous fistulas were made by one surgeon 
at a single medical center. Cross ‑sectional data 
were obtained immediately before the procedure 
and included the clinical assessment of patients, 
CCA ‑IMT measurements, and laboratory tests 
(markers of inflammation, oxidative stress, en‑
dothelial dysfunction, and bone turnover). Pa‑
tients with active infection, positive history of 
hepatitis B or C, HIV infection, renal transplan‑
tation, parathyroidectomy, or neoplastic disease 
were excluded. Detailed medical history includ‑
ing diabetes mellitus, hypertension, dyslipidemia, 
current smoking, duration of dialysis, and medi‑
cations was recorded.
At baseline, 10 ‑year risk of CAD was calculat‑
ed for all patients, using the Framingham risk 
score calculator in accordance with the published 
guidelines.9 Additionally, the CCA ‑IMT was as‑
sessed by ultrasonography in B presentation, us‑
ing Acuson 128 XP/10 (Siemens, United States) 
equipped with a linear head at 5/7 MHz. The mea‑
surements were performed bilaterally at 0.5 cm 
and 2 cm below the division of the common ca‑
rotid artery (CCA) during the diastolic phase of 
the heart cycle. The results were presented as 
the arithmetic means of the values obtained for 
the left and right arteries. 
The study was conducted according to the prin‑
ciples of the Declaration of Helsinki and in com‑
pliance with the International Conference on 
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independent predictors of logarithm‑transformed 
(log) (ADMA), backward stepwise linear regres‑
sion was calculated. Standardized regression coef‑
ficients β (SE) were reported for linear regression. 
Simple and multiple logistic regression (with pre‑
specified covariates) was used to analyze the asso‑
ciation between ADMA concentrations and vas‑
cular calcifications. The resulting odds ratios were 
reported with 95% confidence intervals (CIs). 
The tests were 2 ‑tailed and a P value of 0.05 or 
lower was considered significant. The Statistica 
12 software (StatSoft, Tulsa, Oklahoma, United 
States) was used for calculations.
RESULTS Biochemical test results. The charac‑
teristics of the study group are shown in TABLES 1, 
2, and 3. The study group included 21 predialysis 
patients with stage 5 CKD and 30 patients treat‑
ed with maintenance HD (TABLE 1). Age, sex, and 
the prevalence of traditional cardiovascular risk 
factors did not differ between the groups. Also, 
the groups were comparable in the degree of cal‑
cifications, CCA ‑IMT values, and the presence 
of calcified atherosclerotic plaques in the CCA 
(TABLE 1). Except for diuretics (less commonly 
used among patients on HD) and erythropoi‑
etin (used more often in the HD group), there 
were no significant differences in the prescribed 
drugs (TABLE 1). Serum creatinine, calcium–phos‑
phate product (Ca × Pi) (but not iPTH), OPG, and 
OPN (but not OC and SPARC) levels were higher 
in the HD group. Moreover, selected inflamma‑
tory factors (PTX3, IL ‑6, and sTNFRII) as well as 
TM and ADMA concentrations were higher in di‑
alyzed patients with stage 5 CKD (TABLE 1).
Patients with CKD had higher ADMA con‑
centrations as compared with healthy controls 
dimethylarginine was less than 0.02% and less 
than 0.6%, respectively. The reference range for 
ADMA is 0.26 to 0.64 μmol/l.
SDF1α levels in platelet ‑poor EDTA plasma 
were measured by a commercially available Hu‑
man CXCL12/SDF1α Immunoassay ELISA (R&D 
Systems, Minneapolis, Minnesota, United States). 
The minimum detectable dose for the assay was 
0.018 ng/ml. The intra‑assay and interassay pre‑
cision was 3.9% and 13.4%, respectively. The ref‑
erence range for SDF1α is 1.3 to 2.9 ng/ml.
Inflammatory, calcification, and endothelial 
dysfunction markers were assessed using ELISA 
microplate immunoassays and ELX808 automat‑
ic reader (BIO ‑TEK® Instruments Inc., Wintoos‑
ki, Vermont, United States). The following kits 
were applied: IL ‑6, IL ‑18, PTX3, TNFRII, TM, OPG 
(BioVendor, Brno, Czech Republic); SPARC, OPN, 
and MMP ‑2 (R&D Systems); OC (Metra/Quidel, 
San Diego, California, United States), and FGF‑
‑23 (Immunotopics Int., San Clemente, Califor‑
nia, United States).
Statistical analysis The number of patients (per‑
centage of the respective group) was reported 
for categories. Contingency tables were analyzed 
with the χ2 test. Medians and interquartile rang‑
es (IQRs) were reported for nonnormally dis‑
tributed and means (SD)—for normally distrib‑
uted quantitative variables. Distributions were 
tested for normality with the Shapiro–Wilk test. 
The Mann–Whitney test or the unpaired t test was 
used to assess differences between the groups, ac‑
cording to the distribution. The Pearson corre‑
lation coefficients and linear regression models 
were calculated following logarithmic transfor‑
mation (log) of right ‑skewed variables. To assess 
FIGURE 1 Radial artery 
sections stained with 
alizarin red showing 
calcification of various 
grades; A – grade 1;  
B – grade 2; C – grade 3; 
D – grade 4
A
DC
B
50 μm 50 μm
50 μm50 μm
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TABLE 1 Clinical characteristics of patients and the results of laboratory tests in predialysis patients with stage 5 chronic kidney disease and 
patients on hemodialysis
Parameter Predialysis patients  
(n = 21)
Hemodialysis patients   
(n = 30)
P value
Age, y, mean (SD) 62 (13) 62 (18) 0.8
Male sex, n (%) 13 (62) 18 (60) 0.9
Dialysis therapy duration, mo – 8 (3–38) –
BMI, kg/m2, mean (SD) 27.3 (5.7) 25.6 (6.1) 0.2
Diabetes, n (%) 8 (38) 11 (37) 0.9
Hypertension, n (%) 20 (95) 25 (83) 0.2
Dyslipidemia, n (%) 12 (57) 20 (67) 0.5
Active smoking, n (%) 6 (29) 9 (30) 0.9
Framingham risk score, % 9 (8–20) 11 (6–22) 0.8
Radial artery calcifications, n (%) None 9 (43) 11 (37) 0.7
Grade 1–3 8 (38) 15 (50)
Grade 4 4 (19) 4 (13)
CCA ‑IMT, mma 0.90 (0.75–1.00) 1.00 (0.85–1.05) 0.1
Calcified atherosclerotic plaque in CCA, n (%)b 4 (22) 10 (38) 0.3
ACEIs / ARBs, n (%) 4 (19) 6 (20) 0.9
β ‑blockers, n (%) 13 (62) 21 (70) 0.5
Calcium channel blockers, n (%) 12 (57) 12 (40) 0.2
Diuretics, n (%) 19 (90) 14 (47) 0.001
Number of antihypertensive drugs 3 (2–4) 2 (1–4) 0.3
Statins, n (%) 15 (71) 11 (37) 0.01
Vitamin D, n (%) 6 (29) 12 (40) 0.4
Ca, n (%) 12 (57) 20 (67) 0.5
Erythropoietin, n (%) 1 (5) 15 (50) <0.001
Serum creatinine, μmol/l 389 (512–269) 506 (411–571) <0.001
Ca, mmol/l; mean (SD) 2.20 (0.28) 2.20 (0.19) 0.8
Pi, mmol/l 1.39 (1.27–1.54) 1.62 (1.35–1.86) 0.03
Ca × Pi, mmol2/l2 2.94 (2.69–3.15) 3.60 (2.96–4.16) 0.009
iPTH, pg/ml 303 (186–512) 237 (166–398) 0.6
FGF ‑23, RU/ml 476 (357–1021) 1184 (935–5066) 0.006
OPG, pmol/l 5.44 (3.03–7.77) 9.37 (7.15–14.15) 0.02
OPN, ng/ml 225 (185–315) 356 (270–621) 0.005
OC, ng/ml 41.9 (29.3–51.3) 41.6 (29.0–78.2) 0.4
SPARC, ng/ml 119 (76–159) 106 (79–167) 0.9
Serum albumin, g/l; mean (SD) 42.1 (3.6) 40.0 (6.0) 0.3
PTX3, ng/ml 0.78 (0.52–2.11) 1.79 (1.08–2.93) 0.03
IL ‑6, pg/ml 2.97 (2.06–4.66) 5.82 (2.57–8.57) 0.05
IL ‑18, pg/ml 631 (461–775) 601 (496–905) 0.8
sTNFRII, μg/ml 9.85 (8.92–11.92) 16.64 (11.91–22.34) 0.003
MMP ‑2, ng/ml 216 (187–295) 253 (187–358) 0.4
TM, ng/ml 15.4 (13.9–17.3) 19.4 (14.9–20.4) 0.007
SDF1α, ng/ml 2.90 (2.67–3.38) 3.06 (2.72–3.39) 0.6
ADMA, μmol/l 0.673 (0.655–0.779) 0.885 (0.745–0.978) <0.001
Data are presented as median (interquartile range) unless otherwise stated.
a The results of CCA ultrasound were available for 44 patients, including 18 predialysis and 26 patients on HD.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ADMA, asymmetric dimethylarginine; ARB, angiotensin II receptor blocker; BMI, body 
mass index; CCA, common carotid artery; CCA ‑IMT, common carotid artery intima–media thickness; Ca, calcium; Ca × Pi, calcium–phosphate 
product; FGF ‑23, fibroblast growth factor 23; IL ‑6, interleukin 6; IL ‑18, interleukin 18; iPTH, intact parathyroid hormone; MMP ‑2, matrix 
metalloproteinase 2; OPG, osteoprotegerin; OPN, osteopontin; OC, osteocalcin; Pi, phosphate; PTX3, pentraxin 3; SDF1 ‑α, stromal cell ‑derived 
factor α; SPARC, secreted protein acidic and cysteine rich; sTNFRII, soluble tumor necrosis factor receptor II; TM, thrombomodulin
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P = 0.002), log(FGF ‑23) (r = 0.42; P = 0.003); 
log(OPG) (r = 0.47; P = 0.001), log(OPN) (r = 0.52; 
P <0.001), log(OC) (r = 0.31; P = 0.04); serum albu‑
min (r = –0.33; P = 0.02), log(PTX3) (r = 0.31; P = 
0.04), log(IL ‑6) (r = 0.36; P = 0.01), log(IL ‑18) (r = 
0.29, P = 0.048), log(sTNFRII) (r = 0.59; P <0.001); 
log(MMP ‑2) (r = 0.42; P = 0.003), log(TM) (r = 
0.30; P = 0.03), and SDF1α (r = 0.39; P = 0.005).
Serum creatinine concentrations were not 
correlated with Ca × Pi, FGF ‑23, OPG, OPN, se‑
rum albumin, sTNFRII, MMP ‑2, or SDF1α lev‑
els. In backward stepwise multiple linear regres‑
sion, log(sTNFRII) (β [SE], 0.36 [0.15]; P = 0.02), 
log(MMP ‑2) (β [SE], 0.31 [0.10]; P = 0.003), and 
SDF1α (β [SE], 0.24 [0.11]; P = 0.04) were inde‑
pendent predictors of log(ADMA).
We did not observe any associations between 
ADMA or SDF ‑1 α levels and traditional cardio‑
vascular risk factors. No differences were found in 
ADMA and SDF ‑1 α concentrations between pa‑
tients with diabetes, hypertension, dyslipidemia, 
or active smokers. Moreover, no correlations were 
observed between log(ADMA) or SDF ‑1 α levels 
and age, body mass index (BMI), or the Framing‑
ham risk score.
Histological findings Patients with calcifica‑
tions in the  radial artery had higher ADMA 
concentrations (median [IQR], 0.847 μmol/l 
[0.684–0.978 μmol/l] vs 0.708 μmol/l [0.650–
0.852 μmol/l]; P = 0.029). ADMA levels correlated 
with the calcification grade in patients with grades 
1 to 3 (r = 0.54; P <0.001; FIGURE 2). In contrast, pa‑
tients with most advanced calcifications (grade 4) 
had relatively low concentrations of ADMA (me‑
dian [IQR], 0.724 μmol/l [0.668–0.770 μmol/l]; 
FIGURE 2). In the logistic regression analysis, high 
ADMA levels predicted the presence of radial ar‑
tery calcifications (especially grades 1–3) indepen‑
dently of the HD status and other predictors of 
calcifications such as age, the Framingham risk 
score, and PTX3 concentrations (TABLE 4).
A similar correlation (although weaker) was ob‑
served between SDF1α and Alizarin red staining 
grades 1 to 3 (r = 0.33; P = 0.03; FIGURE 3).
Common carotid artery ultrasound Data from CCA 
ultrasound were available in 44 patients (86%), 
including 28 men and 16 women (mean [SD] 
age, 60 [17] years), of whom 26 (59%) were on 
HD at the start of the study. Of these patients, 
23 had ADMA levels below a median value of 
0.779 µmol/l (ie, the median from the whole 
group) and 21 had ADMA levels above the me‑
dian. CCA ‑IMT values did not differ between pa‑
tients with ADMA below and above the median of 
0.779 µmol/l (median [IQR], 0.87 µmol/l [0.75–
1.05] vs 0.95 µmol/l [0.90–1.10]; P = 0.06), and 
they were not correlated with ADMA concentra‑
tions (r = 0.30; P = 0.06). However, calcified ath‑
erosclerotic plaques in the CCA were more preva‑
lent in patients with ADMA concentrations above 
0.779 µmol/l (11 patients [52%] vs 3 patients 
[13%]; P = 0.005).
(median [IQR], 0.779 [0.672–0.947] μmol/l vs 
0.572 [0.481–0.602] μmol/l; P <0.001). ADMA 
concentrations were higher in HD patients than 
in predialysis patients (TABLE 1), and predialysis 
patients had higher ADMA levels than controls 
(P <0.001). The dialysis status and serum creati‑
nine levels independently predicted ADMA con‑
centrations in multiple regression.
Patients with ADMA concentrations above 
the median were characterized by older age and 
higher levels of Pi, Ca × Pi, FGF ‑23, OPG, OPN, 
PTX, sTNFRII, MMP ‑2, and TM (TABLES 2 and 3). 
Patients with ADMA levels above the median 
more often had calcifications, especially grades 
1 to 3 (FIGURE 1). Furthermore, atherosclerotic 
plaques in the CCA were more prevalent in these 
patients. ADMA levels above the median were 
also associated with more prevalent female sex 
and HD treatment (TABLE 2). There were no asso‑
ciations between drug administration in patients 
with CKD and ADMA concentrations.
Correlations were observed between 
log(ADMA) and the  following parameters: 
log(serum creatinine) (r = 0.38; P = 0.007); 
log(Pi) (r = 0.37; P = 0.008), log(Ca × Pi) (r = 0.43; 
TABLE 2 Clinical characteristics and treatment in patients with stage 5 chronic 
kidney disease depending on the median asymmetric dimethylarginine level
Parameter ADMA P value
<0.779 μmol/l 
(n = 25)
≥0.779 μmol/l 
(n = 26)
Age, y, mean (SD) 57 (17) 67 (13) 0.03
Male sex, n (%) 19 (76) 12 (46) 0.03
Hemodialysis, n (%) 10 (40) 20 (77) 0.007
Dialysis therapy duration, mo,  
median (IQR)a
18 (4–38) 6 (2–38) 0.6
BMI, kg/m2, mean (SD) 26.2 (5.6) 26.3 (6.4) 0.9
Diabetes, n (%) 8 (32) 11 (42) 0.4
Hypertension, n (%) 23 (92) 22 (85) 0.4
Dyslipidemia, n (%) 14 (56) 18 (69) 0.3
Active smoking, n (%) 7 (28) 8 (31) 0.8
Framingham risk score, %,  
median (IQR)
11 (6–22) 11 (7–22) 0.7
Radial artery 
calcifications, n (%)
None 13 (52) 7 (27) 0.01
Grade 1–3 6 (24) 17 (65)
Grade 4 6 (24) 2 (8)
ACEIs / ARBs, n (%) 6 (24) 4 (15) 0.4
β ‑blockers, n (%) 18 (72) 16 (62) 0.4
Calcium channel blockers, n (%) 15 (60) 9 (35) 0.07
Diuretics, n (%) 17 (68) 16 (62) 0.6
Number of antihypertensive drugs, 
median (IQR)
3 (2–4) 2 (1–3) 0.2
Statins, n (%) 13 (52) 13 (50) 0.9
Vitamin D, n (%) 7 (28) 11 (42) 0.3
Ca, n (%) 14 (56) 18 (69) 0.3
Erythropoietin, n (%) 7 (28) 9 (35) 0.6
a Values provided for hemodialyzed patients (n = 30)
Abbreviations: see TABLE 1
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been emphasized by Opalińska et al11 in a study 
on patients with advanced atherosclerosis. The au‑
thors identified the inflamed plaques on scintig‑
raphy using 99mTc ‑labelled interleukin 2 (IL ‑2) in 
the selected group of patients with CKD with high 
cardiovascular risk. ADMA concentrations were 
found to be higher in patients with the highest 
values of IL ‑2 uptake on scintigraphy.8 However, 
in contrast to other studies, we did not observe 
a relation between ADMA levels and CCA‑IMT.12,13
ADMA concentrations in our patients were 
higher than those in our healthy subjects of sim‑
ilar age from European populations and with‑
out evidence of CKD and atherosclerotic vascu‑
lar disease. This corresponds with the results of 
the meta ‑analysis, indicating that patients with 
artery disease have higher ADMA levels than 
healthy controls.10 ADMA levels increased with 
the progression of kidney disease: predialysis pa‑
tients had higher ADMA levels compared with 
healthy participants, and ADMA concentrations 
were higher in patients on HD than in predialy‑
sis patients, which is in line with other reports.14
The available literature includes only a few arti‑
cles on the relationship between ADMA and vas‑
cular calcification, which was confirmed by im‑
aging studies but not by histological examina‑
tion.15-18 The coronary artery calcification (CAC) 
score is regarded as an indicator of the severity 
of atherosclerotic artery disease and may accu‑
rately identify high ‑risk asymptomatic patients 
at the start of dialysis.15 In the CARDIA study,17 
the median value of the ADMA level was higher 
in patients with the presence of CAC on comput‑
ed tomography than in controls. In the logistic re‑
gression model adjusted for age, smoking status, 
alcohol consumption, BMI, waist circumference, 
hypertension, diabetes, low‑ and high ‑density 
lipoprotein and cholesterol, triglycerides, renal 
function, and C ‑reactive protein, the highest ter‑
tile of ADMA (compared with the lowest tertile) 
was associated with an increased odds ratio (1.8) 
of the presence of CAC. By linear regression, an in‑
dependent relationship was also found between 
ADMA and the degree of CAC. 
Our study revealed an association of baseline 
ADMA levels with the severity of radial artery 
calcifications in patients with CKD. In agreement 
with our study, Kobayashi et al18 demonstrated 
that plasma ADMA levels were negatively cor‑
related with GFR and positively correlated with 
the CAC score measured by multidetector ‑row 
computed tomography according to the Agatston 
score. Patients with severe calcifications had high‑
er ADMA levels, insulin resistance measured by 
the homeostasis model assessment of insulin re‑
sistance, and fibrinogen levels, along with the se‑
rum levels of phosphorus, compared with patients 
with mild CAC. In our study, a positive correla‑
tion observed between calcifications and ADMA 
was confirmed by the multiple regression anal‑
ysis, which showed that ADMA levels predict‑
ed artery calcification independently of age, HD 
status, and the Framingham risk score as classic 
DISCUSSION Asymmetric dimethylarginine and arte-
rial calcification Our study showed that elevated 
concentrations of circulating ADMA levels were 
related to a higher risk of medial arterial calcifi‑
cation (MAC) in patients with advanced renal dis‑
ease. So far, the relationship between circulating 
ADMA levels and vascular calcification assessed 
histologically has not been studied. Our data sug‑
gest that excessive accumulation of ADMA in se‑
rum is accompanied by MAC, especially its lower 
grades. In contrast, high concentrations of ADMA 
did not correlate with high CCA ‑IMT values rec‑
ognized as an early marker of subclinical athero‑
sclerosis, although patients with high ADMA lev‑
els more frequently had carotid plaques. We found 
an association between ADMA levels and bone 
turnover parameters, which were increased in pa‑
tients with ADMA concentrations above the me‑
dian value. This finding suggests that ADMA is 
involved in the development of calcifications in 
the intima and media of the arteries.
In recent years, there has been an increasing 
interest in ADMA. Clinical studies included in 
a recent meta ‑analysis demonstrated that pa‑
tients with myocardial infarction as well as with 
stable and unstable angina pectoris had elevat‑
ed plasma ADMA concentrations, thus support‑
ing the hypothesis that ADMA concentrations re‑
flect coronary plaque vulnerability.10 Our research 
confirmed that ADMA concentrations were also 
higher in patients with atherosclerotic plaques 
in the CCA. The importance of ADMA has also 
TABLE 3 Laboratory parameters in patients with stage 5 chronic kidney disease 
depending on the median asymmetric dimethylarginine level
Parameter ADMA P value
<0.779 μmol/l 
(n = 25)
<0.779 μmol/l 
(n = 25)
Creatinine, μmol/l 408 (313–474) 468 (405–547) 0.08
Ca, mmol/l, mean (SD) 2.20 (0.25) 2.20 (0.20) 0.8
Pi, mmol/l 1.38 (1.18–1.64) 1.57 (1.39–1.95) 0.02
Ca × Pi, mmol2/l2 2.91 (2.43–3.39) 3.58 (2.98–4.08) 0.003
iPTH, pg/ml 292 (206–524) 218 (154–343) 0.3
FGF ‑23, RU/ml 504 (292–1243) 1147 (935–3734) 0.02
OPG, pmol/l 5.44 (2.72–7.69) 10.00 (7.70–12.66) 0.002
OPN, ng/ml) 258 (154–357) 354 (253–629) 0.02
OC, ng/ml 41.8 (28.0–59.5) 41.4 (29.4–69.5) 0.5
SPARC, ng/ml 104 (71–139) 126 (88–190) 0.2
Albumin, g/l, mean (SD) 42.2 (3.9) 39.4 (6.0) 0.05
PTX3, ng/ml 0.95 (0.56–2.13) 1.55 (1.08–3.06) 0.03
IL ‑6, pg/ml 2.97 (1.69–6.51) 5.24 (2.89–8.01) 0.1
IL ‑18, pg/ml 575 (428–678) 695 (507–905) 0.09
sTNFRII, μg/ml 9.85 (8.30–12.92) 17.65 (13.70–20.67) <0.001
MMP ‑2, ng/ml 208 (177–256) 291 (229–391) 0.005
TM, ng/ml 15.4 (13.9–17.6) 18.9 (16.9–20.1) 0.05
SDF1α, ng/ml 2.98 (2.57–3.38) 3.11 (2.90–3.39) 0.1
Data are presented as median (interquartile range) unless otherwise stated.
Abbreviations: see TABLE 1
ORIGINAL ARTICLE ADMA as an indicator of artery calcification 163
expressed by alizarin red staining grades 1 to 3. 
Unexpectedly, patients with most advanced cal‑
cifications (grade 4) had relatively low concentra‑
tions of ADMA. It suggests that ADMA ‑induced 
endothelial damage leading to Ca deposition in 
the arterial wall is most pronounced in earlier 
stages of the process and in the further progres‑
sion of calcification (probably influenced by oth‑
er factors, eg, those involved in bone turnover) 
even if ADMA levels decrease.
We also found a positive correlation between 
inflammatory markers (IL ‑6, IL ‑18, sTNFRII) 
and ADMA. These findings are in agreement 
with previous studies, and suggest that ADMA 
may be involved in the inflammatory reaction 
induced by uremia.21-23 Proinflammatory cyto‑
kines and metabolic abnormalities associated 
with systemic inflammation are considered one 
of the principal mechanisms leading to endothe‑
lial dysfunction.24 In the present study, SDF1α, 
sTNFRII, and MMP ‑2 were independent pre‑
dictors of an increased ADMA level. There are 
risk factors, and PTX3 as an acute ‑phase reactant 
synthesized locally at the site of inflammation.
Asymmetric dimethylarginine and selected markers 
of inflammation, endothelial dysfunction, mineral and 
bone disorder, and matrix metalloproteinase 2 In 
patients on HD, the higher ADMA concentration 
is a strong and independent predictor of overall 
mortality and cardiovascular outcome.6 Normal 
endothelial function depends on NO release by 
endothelial cells. ADMA, by competing with L ‑ar‑
ginine, inhibits NO production and may cause en‑
dothelial dysfunction leading to atherosclerotic 
process.7,19 Advanced renal failure is accompanied 
by accumulation of a naturally occurring inhibi‑
tors of NO synthase.20 Endothelial dysfunction, 
as assessed by ADMA levels and inflammation, 
has been consistently linked to atherosclerosis, 
cardiovascular events, and death in patients with 
CKD.21 In our study, there was a correlation be‑
tween ADMA and the severity of calcifications 
in the case of mild and moderate calcifications, 
FIGURE 2 Association 
between serum 
asymmetric 
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concentrations and grade 
of radial artery 
calcification (RAC)
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whereas patients with most advanced calcifica‑
tions (grade 4) had comparatively low concentra‑
tions of SDF1α. Thus, in the uremic environment, 
elevated serum ADMA and SDF1α levels can serve 
as indicators of the vascular calcification process.
Asymmetric dimethylarginine and angiotensin-
-converting enzyme inhibitors or angiotensin recep-
tor blockers ADMA may not only be a marker 
but also an active player in cardiovascular dis‑
ease, which makes it a potential target for ther‑
apeutic interventions. The present study showed 
that the use of angiotensin ‑converting enzyme 
inhibitors (ACEIs) or angiotensin receptor block‑
ers (ARBs) was not significant for ADMA concen‑
trations, while a study by Gamboa et al30 indicat‑
ed that short ‑term use of ACEIs increases ADMA 
levels in patients on HD whereas ARBs do not. 
Interestingly, in the general population without 
kidney injury, ACEIs and ARBs decrease ADMA 
levels.31,32 Also in the current study, no correla‑
tions were found between the administration of 
other drugs (β ‑blocker, calcium channel blocker, 
statin, vitamin D, Ca, erythropoietin) and ADMA 
concentrations.
Limitations Limitations of the present study in‑
clude a relatively low number of participants, 
small size of radial artery fragments, and the fact 
that we relied on a single blood sample per pa‑
tient, collected at baseline. We also acknowledge 
that it is not possible to demonstrate a cause 
and effect relationship on the basis of a cross‑
‑sectional study. Nevertheless, this is the first 
study on the effect of circulating ADMA levels 
on histologically assessed calcification in patients 
with CKD. Our findings support the hypothesis 
that elevated plasma ADMA levels are an impor‑
tant risk factor for cardiovascular disease in pa‑
tients with CKD. High costs limit the application 
of imaging diagnostic methods, such as the as‑
sessment of the CAC score, which in many pa‑
tients with CKD might be replaced by the mea‑
surement of baseline ADMA concentrations for 
the evaluation of cardiovascular risk already at the 
beginning of dialysis.
Conclusions In conclusion, our study is the first 
to report that circulating ADMA levels are 
no data in the available literature on the rela‑
tionship between ADMA and MMP ‑2 levels in 
patients with renal failure. Matrix metallopro‑
teinases are proteolytic enzymes that degrade 
the extracellular matrix and facilitate prolifer‑
ation and migration of endothelial and vascu‑
lar smooth muscle cells which are involved in 
the initiation of calcification.25
The results of the present study indicate that 
circulating ADMA seems to be a key biomarker 
of both MAC and advanced atherosclerosis with 
calcified atherosclerotic plaques. Higher levels of 
Ca × Pi and bone ‑related proteins (FGF ‑23, OPG, 
and OPN) were associated with high ADMA lev‑
els, independently of serum creatinine concen‑
trations. Also, higher concentrations of the en‑
dothelial dysfunction marker SDF1α were corre‑
lated with higher serum ADMA levels. Moreover, 
SDF1α was a predictor of an increased ADMA lev‑
el. Thus, ADMA seems to promote endothelial 
dysfunction. The endothelium, especially in ear‑
ly atherosclerosis, undergoes a constant process 
of injury and repair in order to maintain normal 
vascular function and structure.26 
SDF1α has been shown to induce neovascular‑
ization by recruiting endothelial progenitor cells 
(EPCs) into ischemic tissues by an increased cou‑
pling of SDF1α/C ‑X‑C motif chemokine type ‑4 re‑
ceptor.27 Gossl et al28 identified a subgroup of bone 
marrow–derived circulating EPCs with an osteo‑
genic phenotype (expressing the osteoblast mark‑
er OC) and found that patients with coronary en‑
dothelial dysfunction have higher numbers of cir‑
culating OC(+) EPCs compared with patients with 
normal endothelial function. In cell culture, cir‑
culating EPCs with high expression of OC were 
capable of forming mineralized deposits. Anoth‑
er study showed that in contrast to controls, pa‑
tients with coronary endothelial dysfunction re‑
tain osteogenic EPCs within the coronary circula‑
tion, and this retention is accompanied by the re‑
lease of SDF1α and interleukin 8.29 The authors 
concluded that retention of osteogenic EPCs for 
endothelial repair may lead to the induction and 
progression of coronary calcification rather than 
to normal repair. In our study, similarly to the re‑
sults obtained for ADMA, patients with calcifica‑
tion grades 1 to 3 showed a correlation between 
SDF1α concentrations and the calcification grade, 
TABLE 4 Logistic regression analysis to predict radial artery calcifications as detected with alizarin red staining
Radial artery calcifications
Independent variable Grade 1–4, OR (95% CI) Grade 1–3, OR (95% CI)
Simple model Multiple model Simple model Multiple model
ADMA, per 10 μmol/l 1.49 (1.02–2.16) 1.76 (1.03–3.03) 1.71 (1.12–2.61) 2.29 (1.15–5.86)
Age, per 1 year – 1.03 (0.97–1.09) – 1.07 (0.98–1.16)
Hemodialysis – 0.92 (0.17–4.99) – 0.41 (0.04–4.50)
Framingham risk score, 
per 1%
– 1.06 (0.96–1.18) – 1.05 (0.94–1.16)
PTX3, per 1 ng/ml – 0.97 (0.57–1.64) – 0.87 (0.51–1.49)
Abbreviations: CI, confidence interval; OR, odds ratio; others, see TABLE 1
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an indicator of MAC in patients with CKD and 
suggests that plasma ADMA levels could be a use‑
ful, simple biomarker of cardiovascular risk in dai‑
ly clinical practice.
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